Laura Sepp-Lorenzino

Laura Sepp-Lorenzino, PhD joined Intellia Therapeutics in 2019 as chief scientific officer and is responsible for research and early development. Intellia’s leading CRISPR platform supports a full-spectrum therapeutic strategy. Laura previously held leadership positions at Vertex, Alnylam, and Merck.